Do­va picked up its new­ly ap­proved drug castoff for a song — but pay­ers will be singing the blues about the price

Do­va $DO­VA didn’t have to pay much when it bagged the rights to Doptelet (ava­trom­bopag) from Ei­sai — lay­ing out on­ly $5 mil­lion for the castoff. And now that the FDA has come through with a mar­ket­ing ap­proval for a set of chron­ic liv­er dis­ease pa­tients suf­fer­ing from low blood platelet counts, it’s not pass­ing on any of the sav­ings.

Do­va re­port­ed to­day that it’s slapped a whole­sale list price of $9,000 for the 40 mg dai­ly dose and $13,500 for the 60 mg dai­ly dose, which raised the eye­brows of Leerink’s Ge­of­frey Porges — who’s been track­ing the launch.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER